Ceftazidime-Decorated Gold Nanoparticles: a Promising Strategy against Clinical Ceftazidime-Avibactam-Resistant Enterobacteriaceae with Different Resistance Mechanisms

Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0026223. doi: 10.1128/aac.00262-23. Epub 2023 Jun 26.

Abstract

Nanoparticle-based antibiotic delivery systems are essential in combating antibiotic-resistant bacterial infections arising from acquired resistance and/or biofilm formation. Here, we report that the ceftazidime-decorated gold nanoparticles (CAZ_Au NPs) can effectively kill clinical ceftazidime-avibactam-resistant Enterobacteriaceae with various resistance mechanisms. Further study of underlying antibacterial mechanisms suggests that CAZ_Au NPs can damage the bacterial cell membrane and increase the level of intracellular reactive oxygen species. Moreover, CAZ_Au NPs show great potential in inhibiting biofilm formation and eradicating mature biofilms via crystal violet and scanning electron microscope assays. In addition, CAZ_Au NPs demonstrate excellent performance in improving the survival rate in the mouse model of abdominal infection. In addition, CAZ_Au NPs show no significant toxicity at bactericidal concentrations in the cell viability assay. Thus, this strategy provides a simple way to drastically improve the potency of ceftazidime as an antibiotic and its use in further biomedical applications.

Keywords: Enterobacteriaceae; antimicrobial resistance; ceftazidime-avibactam; gold nanoparticles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Azabicyclo Compounds / pharmacology
  • Ceftazidime* / pharmacology
  • Drug Combinations
  • Enterobacteriaceae
  • Gold
  • Metal Nanoparticles*
  • Mice
  • Microbial Sensitivity Tests

Substances

  • avibactam, ceftazidime drug combination
  • Ceftazidime
  • Gold
  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Drug Combinations